TY  - CHAP
AU  - Herrera García José Carlos
AU  - Arellano Montellano Ek Ixel
AU  - Jaramillo
Arellano Luis Enrique
AU  - Espinosa Arellano Andrea
AU  - Martínez Flores
Alejandra Guadalupe
AU  - Caballero López Christopherson Gengyny
ED  - Kuan-Hsiang Gary Huang
ED  - Chen Hsuan Sherry Tsai
Y1  - 2018-02-07
PY  - 2018
T1  - Use of Omalizumab as Treatment in Patients with Moderate and Severe Non-Atopic Asthma and Associated with Asthma- COPD Overlap Syndrome (ACOS)
N2  - Asthma is a severe and growing threat affecting both children and adults in both developing and developed world, currently affecting approximately 8% of US population. It is becoming increasingly recognized as a syndrome constituted by airway obstruction, airway hyperresponsiveness, and airway inflammation with different causes, associated risk factors, and underlying pathophysiology. The advances in basic and clinical research of asthma have accelerated over the past 20 years with increasing diagnostic tools, especially biomarkers, that led to specific characterization of individual patient's asthma pathophysiology, or disease "phenotype" and "endotype," which allowed precision medicine therapies, including new asthma biologics. This book aims to update the paradigm shifts in precision medicine of asthma diagnosis and management, driven by underlying phenotypes or endotypes.
BT  - Asthma Diagnosis and Management
SP  - Ch. 11
UR  - https://doi.org/10.5772/intechopen.73904
DO  - 10.5772/intechopen.73904
SN  - 978-1-78923-323-0
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-25
ER  -